Therapy Areas: Cardiovascular
AstraZeneca licenses Lp(a) asset from CSPC
7 October 2024 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) announced on Monday that it has entered into a licence agreement with CSPC Pharmaceutical Group Ltd (HKG:109...
Medinol completes First-in-Human implantation of ChampioNIR Drug-Eluting Peripheral Stent in Australia
7 October 2024 - Cardiovascular intervention company Medinol Ltd announced on Monday the successful First-in-Human implantation of its ChampioNIR Drug-Eluting Peripheral Stent by Drs Gerard S. Goh and...
Rivus Pharmaceuticals reveals new clinical data from HU6 Phase 2a HuMAIN study
1 October 2024 - Clinical-stage biopharmaceutical company Rivus Pharmaceuticals, Inc. announced on Monday positive results from its Phase 2a HuMAIN trial evaluating HU6 in patients with obesity-relate...
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
30 September 2024 - US-based global medical technology company Boston Scientific Corporation (NYSE: BSX) announced on Friday that it has received approval from Pharmaceuticals and Medical Device Agenc...
Genetesis' CardioFlux Magnetocardiograph receives Health Canada approval
23 September 2024 - US magnetocardiography (MCG) company Genetesis Inc announced on Friday that it has received approval from Health Canada for its CardioFlux Magnetocardiograph (CardioFlux MCG) with ...
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
16 September 2024 - UK-based life sciences company Avacta Group plc (AIM: AVCT) announced on Monday that it presented updated Phase 1 clinical data for AVA6000, a pre|CISION-enabled doxorubicin, at th...